Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas

Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas

The distinct molecular subtypes of lung cancer are defined by monogenic biomarkers, such as <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> rearrangement. Tumor mutation burden (TMB) is a potential biomarker for response to immunotherapy, which is one of the measures for...

Full description

Bibliographic Details
Main Authors: Changzheng Wang, Han Liang, Cong Lin, Fuqiang Li, Guoyun Xie, Sitan Qiao, Xulian Shi, Jianlian Deng, Xin Zhao, Kui Wu, Xiuqing Zhang
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:International Journal of Molecular Sciences
Subjects:
Tumor mutation burden
molecular subtype
lung adenocarcinomas
<i>RYR2</i>
Online Access:https://www.mdpi.com/1422-0067/20/17/4251

Internet

https://www.mdpi.com/1422-0067/20/17/4251

Similar Items